– USA, CA – Shasqi, Inc. a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced the additions of Dr. Pamela Klein (M.D.) and Dr. Mark McCamish (M.D., Ph.D.) to its Board of Directors.
About Dr. Pamela Klein
Dr. Klein is an Independent Director on several biotech boards, as well as a venture partner for Ysios Capital. She has previously held positions at Genentech, and the NCI as co-founder and Research Director of NCI-Navy Breast Center.
Dr. Mark McCamish
Dr McCamish is the President and CEO of IconOVir Bio, an oncolytic virus-based biotech creating potent viruses that bind broadly to solid tumors and replicate selectively in tumor cells. He has held previous roles as the President and CEO of Forty-Seven and the Global Head of Development at Sandoz, preceded by several CMO roles at small biotech companies, as well as senior leadership positions at Amgen and Abbott.
About Shasqi and CAPAC
Shasqi’s unique CAPAC (Click Activated Protodrugs Against Cancer) platform uses 2022 Nobel Prize-winning technology, click chemistry, to selectively activate high doses of cancer drugs directly at the site of the tumor, minimizing toxicity to healthy cells and potentially improving the therapeutic index by dramatically altering the exposure.
CAPAC builds on the advances achieved by antibody-drug conjugates, changing what’s possible with antigen-targeted drug activation. Shasqi has developed an expansive and diverse library of antigen-targeting activators and cancer-therapeutic protodrugs. These two components are decoupled from each other and united at the site of the tumor via a click chemistry reaction. We are the first company to use click chemistry in humans.
Shasqi is advancing the development of new tumor-targeting activators and prodrugs on an ongoing basis and is in active collaboration with partners in the biopharmaceutical industry to expand the CAPAC library of antigen-targeting activators and prodrugs.
For more information: https://www.shasqi.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
